Cancer-associated somatic mutations in human phosphofructokinase-1 reveal a critical electrostatic interaction for allosteric regulation of enzyme activity

Abstract excerpt

Metabolic reprogramming, including increased glucose uptake and lactic acid excretion, is a hallmark of cancer. The glycolytic 'gatekeeper' enzyme phosphofructokinase-1 (PFK1), which catalyzes the step committing glucose to breakdown, is dysregulated in cancers. While altered PFK1 activity and expression in tumors have been demonstrated, little is known about the effects of cancer-associated somatic mutations....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Hypoxia, and Metabolism
• Share to Metabolism, Diabetes, and Cancer
• Share to Pancreatic function and diabetes